Figure 7: 3PO plus SU5416 combo-therapy normalizes pathological vessels.
From: Glycolytic regulation of cell rearrangement in angiogenesis
(a–d) Representative images of VEGF-containing Matrigel plugs treated with control vehicle (a), the PFKFB3 blocker 3PO (b), the VEGFR2 inhibitor SU5416 (c), and a combination treatment of 3PO plus SU5416 (d), and immunostained for the EC marker CD105 (red) and the pericyte marker NG2 (green). Scale bar, 40 μm. (e) Quantification of the NG2-coverage of vessels in the Matrigel model, treated with control vehicle (DMSO, grey), 3PO (blue), SU5416 (red), or 3PO plus SU5416 (green). Data are mean±s.e.m.; n=3–5 Matrigel plugs per condition; NS: not significant, **P<0.01, ***P<0.001; Student’s t-test. (f) Blood vessel tortuosity in the Matrigel model, treated with control vehicle (DMSO, grey), 3PO (blue), SU5416 (red), or 3PO plus SU5416 (green), was analysed semi-quantitatively by an observer blinded for the conditions. Data are mean±s.e.m.; n=3–5 Matrigel plugs per condition; NS, not significant; *P<0.05; Two-tailed Wilcoxon rank-sum test for equal medians.
